Revolution Medicines ceo salary
Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, Inc. (RVMD), received $14,672,390 ($14.7M) in total compensation for FY2025, up 45.6% from the prior year. Option awards of $8,995,114 were the largest component. Figures come from Revolution Medicines, Inc.'s DEF 14A filed 27 Apr 2026 (accession 0001193125-26-182453).
Reported total from the latest DEF 14A pay table. Source filing (accession 0001193125-26-182453). These figures come from Revolution Medicines, Inc.'s DEF 14A filed 27 Apr 2026 (accession 0001193125-26-182453).
| Component | Amount |
|---|---|
| Salary | $812,500 |
| Stock awards | $3,968,076 |
| Option awards | $8,995,114 |
| Cash incentive | $889,700 |
| Other | $7,000 |
| Total | $14,672,390 |
FAQ
See also: RVMD ticker page